Clinical Trials
35 trialsA Study of Pembrolizumab in People With Ultra-Rare Sarcomas
Memorial Sloan Kettering Cancer Center
Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma
University of California, San Francisco
I-SPY
QuantumLeap Healthcare Collaborative
SPiReL
Sunnybrook Health Sciences Centre
A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma
Memorial Sloan Kettering Cancer Center
A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
Memorial Sloan Kettering Cancer Center
A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg
Memorial Sloan Kettering Cancer Center
Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
M.D. Anderson Cancer Center
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
Mayo Clinic
Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
Mayo Clinic
Pembrolizumab in Neoplasms or Lymphomas
Dana-Farber Cancer Institute
PULSAR
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
Mayo Clinic
PEMBROSARC
Institut Bergonié
EFTISARC-NEO
Maria Sklodowska-Curie National Research Institute of Oncology
NeoSarc
Gustave Roussy, Cancer Campus, Grand Paris
A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
Memorial Sloan Kettering Cancer Center
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Dana-Farber Cancer Institute
Pembrolizumab in Treating Patients With Recurrent Glioblastoma
M.D. Anderson Cancer Center
Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma
Yonsei University
SOC-2320
Sarcoma Oncology Research Center, LLC
Pembrolizumab and Pemetrexed for Progressive Chordoma
Saint John's Cancer Institute
Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas
University of Miami
Epacadostat and Pembrolizumab in Patients With GIST
Columbia University
AcSé
UNICANCER
Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma
Wake Forest University Health Sciences
Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma
National Cancer Institute (NCI)
PROPANE
Herlev and Gentofte Hospital
CAPTIVE
DNAtrix, Inc.
A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery
Oslo University Hospital
Poly-ICLC
Oncovir, Inc.
PROMO
Oslo University Hospital
SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
Sarcoma Alliance for Research through Collaboration
Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a
GlaxoSmithKline
KAPKEY
Assistance Publique - Hôpitaux de Paris